Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
前日終値
$21.26
+$0.05 · +0.24%
日中の時刻はETです。市場データは遅延する場合があります。
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
日中レンジ
現在 $21.26
52週レンジ
現在 $21.26
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
60
適正価値
センチメント
72
強気
リスク
64
高リスク
モメンタム
26
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
日中レンジ
現在 $21.26
52週レンジ
現在 $21.26
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 4.41億 USD | 3.89億 USD | 3.54億 USD | 3.14億 USD | 2.99億 USD |
| 売上原価 | 1.71億 USD | 1.4億 USD | 1.25億 USD | 1.11億 USD | 1.01億 USD |
| 粗利益 | 2.7億 USD | 2.49億 USD | 2.29億 USD | 2.03億 USD | 1.98億 USD |
| 研究開発 | 3099.1万 USD | 2845.2万 USD | 2870.7万 USD | 3887.9万 USD | 3554.6万 USD |
| 販売・一般管理 | 2.13億 USD | 1.92億 USD | 2.09億 USD | 1.57億 USD | 1.7億 USD |
| 営業費用 | 2.44億 USD | 2.1億 USD | 2.23億 USD | 1.96億 USD | 1.89億 USD |
| 受取利息 | 76.3万 USD | 146.7万 USD | 107.7万 USD | 14.7万 USD | 7.9万 USD |
| 支払利息 | 2658.2万 USD | 3427.7万 USD | 2529.9万 USD | 1822.4万 USD | 1688.7万 USD |
| 減価償却費と償却費 | 2245.8万 USD | 2420.5万 USD | 2307.6万 USD | 2244.2万 USD | 2397.7万 USD |
| 営業利益 | 2674.5万 USD | 3887.4万 USD | 574.2万 USD | 620.1万 USD | 811.7万 USD |
| 純利益 | 976.8万 USD | −1335.9万 USD | −3069万 USD | −1919.2万 USD | −1483.4万 USD |
会社概要が更新されました 2026年10月11日.
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$42.50
上昇余地(99.91%)| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2000年12月28日 | 3:2 | — | — |
株式分割 | 1996年7月1日 | 2:1 | — | — |
発効済み 2000年12月28日
3:2
発効済み 1996年7月1日
2:1
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3949.55万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM2546.32万0.03%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF1340.47万0.01%954億 USD0.05%$235+0.80%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM949.78万0.06%158.4億 USD0.03%$53.45+0.17%
iShares Russell 2000 Growth ETFIWO895.46万0.06%139.17億 USD0.24%$356.78+0.94%
Dimensional - US Small Cap ETFDFAS737.78万0.02%338.69億 USD0.31%$78.35+0.32%
Vanguard Russell 2000 ETFVTWO709.13万0.04%180億 USD0.06%$112.66+0.50%
State Street SPDR S&P 600 Small Cap Growth ETFSLYG607.13万0.13%47.76億 USD0.15%$108.57+0.70%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
iShares Russell 2000 Growth ETFIWO
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
State Street SPDR S&P 600 Small Cap Growth ETFSLYGAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。